Live tape
Top 8, mentions 7d18,258MSFT3,395 mentions▲ +0.09AAPL2,656 mentions▲ +0.07GOOGL2,634 mentions▲ +0.05META2,225 mentions▲ +0.04SNDK2,157 mentions▲ +0.06NVDA1,838 mentions▲ +0.07SPCX1,708 mentions▲ +0.06AMZN1,645 mentions▲ +0.10

Equity · Healthcare

ONCO

Onconetix, Inc. · NasdaqCM

$0.77 −2.86% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart Chart by TradingView
Track this symbol on TradingView

The chart above plots the price of ONCO over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 55 sessions over that window: $6.42 on 4 May 2026 through $0.77 on 17 July 2026. Finazon · prior-day close.

Market cap $8.8M
Avg volume 41.6K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 2, 2026

ONCO insider trades

SEC Form 4

ONCO has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 15 August 2025.

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
15 Aug 2025 Ramdeen Timothy R. Other (filer-described) 39
15 Aug 2025 Meier Thomas Other (filer-described) 39
15 Aug 2025 Tarsh Simon Other (filer-described) 39
15 Aug 2025 Oakley Andrew John Other (filer-described) 20
15 Aug 2025 Ramdeen Timothy R. Award 618
15 Aug 2025 Meier Thomas Award 618
15 Aug 2025 Tarsh Simon Award 618
15 Aug 2025 Oakley Andrew John Award 618
14 Jul 2025 Altos Venture AG Other (filer-described) 241,514

ONCO reported financials

SEC EDGAR XBRL

ONCO reported revenue of $815K for the fiscal year ended 31 Dec 2025. Net income over the same period was −$14.0M.

Figure Reported Period
Revenue $815K 31 Dec 2025 fiscal year
Net income −$14.0M 31 Dec 2025 fiscal year
Diluted EPS −$16.56 31 Dec 2025 fiscal year
Total assets $14.8M 31 Mar 2026 at period end
Total equity $11.7M 31 Mar 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 31 Mar 2026

ONCO earnings

SEC EDGAR
Date Period EPS Revenue
31 Mar 2026 Q1 2026 $-6.71 $0M
31 Dec 2025 FY 2025 $-16.56 $1M
30 Sep 2025 Q3 2025 $-6.25 $0M
30 Jun 2025 Q2 2025 $-4.76 $0M
31 Mar 2025 Q1 2025 $-227.25 $0M
31 Dec 2024 FY 2024 $-1,823.39 $3M
30 Sep 2024 Q3 2024 $-249.08 $0M
30 Jun 2024 Q2 2024 $-2,191.59 $1M

Reported figures & scheduled dates · SEC EDGAR filings

ONCO institutional holders

SEC Form 13F

0 of the 45 institutional funds we track reported a ONCO position for the quarter ended 31 Dec 2025; the latest of those filings landed 17 Feb 2026.

Fund Action Shares Value
Citadel Advisors Exited

Source: SEC EDGAR 13F filings

ONCO fails-to-deliver

SEC CNS data

On 14 Jul 2026, 7,998 shares of ONCO failed to deliver (about $7K) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
14 Jul 2026 7,998 $7K 0.070%
13 Jul 2026 10,912 $10K 0.095%
09 Jul 2026 16,609 $16K 0.145%
08 Jul 2026 17,484 $19K 0.153%
07 Jul 2026 109,939 $121K 0.959%
06 Jul 2026 6,316 $6K 0.055%
02 Jul 2026 46,630 $50K 0.407%
01 Jul 2026 14,230 $16K 0.124%
30 Jun 2026 3 $3 <0.001%
29 Jun 2026 3 $3 <0.001%
26 Jun 2026 3 $3 <0.001%
25 Jun 2026 103,828 $104K 0.906%
24 Jun 2026 1,797 $2K 0.016%
23 Jun 2026 12,003 $11K 0.105%

Source: SEC fails-to-deliver (CNS) data